Glaukos Corp. ( (GKOS) ) has released its Q3 earnings. Here is a breakdown of the information Glaukos Corp. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) and continues to advance its portfolio with novel, dropless platform technologies.
In its latest earnings report, Glaukos announced record net sales of $133.5 million for the third quarter of 2025, marking a 38% increase year-over-year. The company also raised its 2025 net sales guidance to a range of $490 million to $495 million and introduced preliminary 2026 guidance of $600 million to $620 million, reflecting strong business momentum.
Key financial highlights include a significant 45% year-over-year increase in glaucoma sales, with U.S. glaucoma sales rising by 57%. The gross margin improved to approximately 78%, with a non-GAAP gross margin of approximately 84%. Despite increased SG&A and R&D expenses, the company reduced its net loss to $16.2 million, or $0.28 per diluted share, compared to a net loss of $21.4 million in the same quarter last year.
Looking ahead, Glaukos remains focused on executing its strategic plans and advancing its robust pipeline to improve patient outcomes in chronic eye diseases. The company’s management is optimistic about sustaining growth and achieving its financial targets for the coming years.